--- title: "Cobot Demand Drives Yuejiang's 114% Sales Surge as Consumer Brands Defy Margin Pressures" type: "News" locale: "en" url: "https://longbridge.com/en/news/296211364.md" description: "Yuejiang Technology's robotics revenue doubled in H1 2026 despite widening losses, while Auntea Jenny posted a 58% profit jump. Traditional players like COSCO pivot to debt markets as earnings contract." datetime: "2026-08-18T10:12:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296211364.md) - [en](https://longbridge.com/en/news/296211364.md) - [zh-HK](https://longbridge.com/zh-HK/news/296211364.md) generator: "portal-rs" --- # Cobot Demand Drives Yuejiang's 114% Sales Surge as Consumer Brands Defy Margin Pressures A stark divergence in first-half 2026 earnings is sweeping across Chinese consumer and advanced manufacturing sectors, with robotics makers prioritizing scale over immediate profitability. Shenzhen Yuejiang Technology (2432.HK) is leading the top-line acceleration, projecting H1 revenue of up to 330 million yuan—a 114% year-over-year surge driven by robust demand for collaborative robots. However, heavy early-stage investments in embodied AI have widened its net loss to as much as 120 million yuan. Consumer beverage chains are proving significantly more resilient on the bottom line. Auntea Jenny (2589.HK) reported a 58% jump in first-half net profit to 321 million yuan, alongside a 42% increase in revenue to 2.59 billion yuan. Conversely, traditional heavyweights are navigating severe margin compression. COSCO SHIPPING Development (2866.HK) saw Q1 net income drop 14% to 413 million yuan, prompting the company to float a proposed 6 billion yuan corporate bond to fortify its balance sheet and fund a 15-vessel order. Beverage distributor China Foods (0506.HK) is also grappling with softening sales momentum despite a solid 22 billion yuan historical revenue base. In the biotech and healthcare space, catalysts remain heavily pipeline-dependent. Jacobio Pharmaceuticals (1167.HK) is deploying a 100 million HKD buyback program after securing a $100 million upfront payment for its pan-KRAS inhibitor, which continues to clear clinical hurdles. Sinopharm Group (1099.HK) maintained its defensive posture in Q1, offering stability amid market choppiness. Meanwhile, MGM China (2282.HK) continues to ride the broader recovery metrics in Macau's gaming sector. Among micro-cap players, short-term lender Capital Finance Holdings (8239.HK), apparel supply chain manager i.century Holding (8507.HK), and retail operator Shun Ke Long (0932.HK) are navigating a tight liquidity environment as controlling shareholders maintain their firm grips on equity, limiting broader market participation. ### Related Stocks - [01167.HK](https://longbridge.com/en/quote/01167.HK.md) - [02432.HK](https://longbridge.com/en/quote/02432.HK.md) - [02589.HK](https://longbridge.com/en/quote/02589.HK.md) - [02866.HK](https://longbridge.com/en/quote/02866.HK.md) - [02282.HK](https://longbridge.com/en/quote/02282.HK.md) - [08239.HK](https://longbridge.com/en/quote/08239.HK.md) - [01099.HK](https://longbridge.com/en/quote/01099.HK.md) - [08507.HK](https://longbridge.com/en/quote/08507.HK.md) ## Related News & Research - [Linkage Global signs LOI for up to US$20 million Class A share PIPE with Capital Finance Limited](https://longbridge.com/en/news/298914399.md) - [CLSA Ratings, TPs on Casinos (Table)](https://longbridge.com/en/news/299122149.md) - [CLSA Cuts Macau GGR Forecasts for Next 2 Years by 3%-4%; Turns More Cautious on Outlook, GALAXY ENT Top Pick](https://longbridge.com/en/news/299121470.md) - [MGM China buys MGM Asia Pacific for US$20 million](https://longbridge.com/en/news/291269156.md) - [MGM CHINA To Provide Comprehensive Services for High-end Clientele, Continue Renovation of MGM Macau Suites](https://longbridge.com/en/news/294299120.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**